14 research outputs found

    Gravity waves in severe weather

    Get PDF
    With a view to determining the role of severe weather in producing gravity waves, two tests were made. In the first, the wind speed measured at two nearby radiosonde stations, Peoria and Salem, was correlated with the stratosphere gravity-wave intensity at Urbana. Although the gravity-wave intensity fluctuated greatly from day to day, these is little if any correlation with the stratospheric wind speed. This suggests that orographic forcing is not a factor in generating gravity waves in Urbana. On the other hand, a clear correlation is found between cloud to heights exceeding 20,000 ft and an increased gravity-wave amplitude in the stratosphere

    A study of electron density profiles in relation to ionization sources and ground-based radio wave absorption measurements, part 1

    Get PDF
    An extensive set of ground-based measurements of the diurnal variation of medium frequency radio wave adsorption and virtual height is analyzed in terms of current understanding of the D- and lower E-region ion production and loss process. When this is done a gross discrepancy arises, the source of which is not known

    A study of electron density profiles in relation to ionization sources and ground-based radio wave absorption measurements, part 2

    Get PDF
    The D-region ion production functions are used to calculate the relationship between radio wave absorption and the flux level of X-rays in the 1-8A wavelength band. In order to bring this calculation into agreement with the empirically established relationship, it was found necessary to reduce by, a factor of about 5, the Meira nitric oxide densities below 90 km

    Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

    Get PDF
    Dimethyl fumarate (DMF) inhibits inflammasome-mediated inflammation and has been proposed as a treatment for patients hospitalised with COVID-19. This randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple treatments in patients hospitalised for COVID-19 (NCT04381936, ISRCTN50189673). In this assessment of DMF performed at 27 UK hospitals, adults were randomly allocated (1:1) to either usual standard of care alone or usual standard of care plus DMF. The primary outcome was clinical status on day 5 measured on a seven-point ordinal scale. Secondary outcomes were time to sustained improvement in clinical status, time to discharge, day 5 peripheral blood oxygenation, day 5 C-reactive protein, and improvement in day 10 clinical status. Between 2 March 2021 and 18 November 2021, 713 patients were enroled in the DMF evaluation, of whom 356 were randomly allocated to receive usual care plus DMF, and 357 to usual care alone. 95% of patients received corticosteroids as part of routine care. There was no evidence of a beneficial effect of DMF on clinical status at day 5 (common odds ratio of unfavourable outcome 1.12; 95% CI 0.86-1.47; p = 0.40). There was no significant effect of DMF on any secondary outcome

    Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

    Get PDF
    Dimethyl fumarate (DMF) inhibits inflammasome-mediated inflammation and has been proposed as a treatment for patients hospitalised with COVID-19. This randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple treatments in patients hospitalised for COVID-19 (NCT04381936, ISRCTN50189673). In this assessment of DMF performed at 27 UK hospitals, adults were randomly allocated (1:1) to either usual standard of care alone or usual standard of care plus DMF. The primary outcome was clinical status on day 5 measured on a seven-point ordinal scale. Secondary outcomes were time to sustained improvement in clinical status, time to discharge, day 5 peripheral blood oxygenation, day 5 C-reactive protein, and improvement in day 10 clinical status. Between 2 March 2021 and 18 November 2021, 713 patients were enroled in the DMF evaluation, of whom 356 were randomly allocated to receive usual care plus DMF, and 357 to usual care alone. 95% of patients received corticosteroids as part of routine care. There was no evidence of a beneficial effect of DMF on clinical status at day 5 (common odds ratio of unfavourable outcome 1.12; 95% CI 0.86-1.47; p = 0.40). There was no significant effect of DMF on any secondary outcome

    Equatorial Ionospheric Absorption at Different Longitudes

    No full text

    Thigh-length compression stockings and DVT after stroke

    Get PDF
    Controversy exists as to whether neoadjuvant chemotherapy improves survival in patients with invasive bladder cancer, despite randomised controlled trials of more than 3000 patients. We undertook a systematic review and meta-analysis to assess the effect of such treatment on survival in patients with this disease
    corecore